Mont-Saint-Guibert, Belgium – July 27, 2022 — Nyxoah SA (Euronext Brussels/Nasdaq: NYXH), a pioneering medical technology firm focused on developing and commercializing innovative solutions for Obstructive Sleep Apnea (OSA), has announced its participation in the Canaccord Genuity 42nd Annual Growth Conference, set to occur in Boston, Massachusetts, from August 8 to 11, 2022.

Olivier Taelman, the Chief Executive Officer of Nyxoah, will present a corporate update on Wednesday, August 10, 2022, at 3:30 PM EDT. A live webcast of the presentation will be accessible through the Events section of Nyxoah’s Investor Relations website. The company will also engage in one-on-one meetings with institutional investors attending the conference.

Nyxoah’s latest Investor Presentation is available on the Shareholder Information section of its Investor Relations page.

About Nyxoah
Nyxoah is dedicated to advancing medical technology solutions for treating Obstructive Sleep Apnea (OSA). Its flagship product, the Genio® system, is a leadless and battery-free hypoglossal neurostimulation therapy designed to address OSA, the most prevalent sleep-disordered breathing condition linked to increased mortality and cardiovascular issues. Nyxoah envisions a future where OSA patients can experience restful nights and lead fulfilling lives.

After the successful completion of the BLAST OSA study, the Genio® system received its European CE Mark in 2019. The company successfully conducted initial public offerings on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the favorable results from the BETTER SLEEP study, Nyxoah obtained CE mark approval to expand its therapeutic indications to include Complete Concentric Collapse (CCC) patients, a demographic currently excluded from competitor therapies. Furthermore, Nyxoah is conducting the DREAM IDE pivotal study in pursuit of FDA approval for U.S. commercialization.